Finance

Lists
Q3 2026 earnings • released • EPS beat +8.03% • Revenue miss -10.71%
See results
EBS:NYSE
Emergent Biosolutions Inc
$6.06
+3.59%
(+0.21) 1D
$5.97
-1.49% (-0.090)
After hours
Closed: Nov 6, 4:00:03 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for EBS...
Open
$5.79
High
$6.07
Low
$5.78
Mkt. cap
311.58M
Avg. vol.
1.12M
Volume
1.00M
52-wk high
$14.06
52-wk low
$4.36
EPS
-$3.51
Beta
2.37
Shares outstanding
51.42M
No. of employees
900
Open
$5.79
High
$6.07
Low
$5.78
Mkt. cap
311.58M
Avg. vol.
1.12M
Volume
1.00M
52-wk high
$14.06
52-wk low
$4.36
EPS
-$3.51
Beta
2.37
Shares outstanding
51.42M
No. of employees
900
News stories
From web sources and news partners
Profile
Emergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland. It develops vaccines and antibody therapeutics for infectious diseases and opioid overdoses, and it provides medical devices for biodefense purposes. Among the company's products are the controversial BioThrax, the only anthrax vaccine licensed by the U.S. Food and Drug Administration and Narcan for the emergency treatment of opioid overdose. The company also manufactures pharmaceuticals for infectious diseases like cholera and typhoid. During the COVID-19 pandemic, Emergent BioSolutions also produced Johnson & Johnson/Janssen and Oxford–AstraZeneca vaccines at one of its plants; however, this was marked by contamination and other production issues, and millions of doses of vaccine had to be discarded. Wikipedia
About Emergent Biosolutions Inc
CEORobert G. Kramer Sr. | Joseph C. Papa
Employees900
FoundedSep 5, 1998
HeadquartersRockville, Maryland, United States
SectorHealth Care
IndustryBiotechnology
Websiteemergentbiosolutions.com
Analyst ratings
Based on 2 analysts giving stock ratings to EBS in the past 3 months
Hold
Buy
1
Hold
0
Sell
1
12-month forecast
Based on 2 Wall Street analysts offering 12 month price targets for EBS in the last 3 months.
Highest
Current $6.06
$10.00 (+65.02%)
Average
$10.00 (+65.02%)
Lowest
$10.00 (+65.02%)
Analyst
Recommendation
Action
Price target
Projected
Date
Ram Selvaraju
H.C. Wainwright
Buy
Reiterated
$10.00
+65%
09/09/2026
Jessica Fye
J.P. Morgan
Sell
Initiated
-
-
08/21/2026
Last report
Nov 3, 2026
Fiscal period
Q3 2026
-$0.36 / -$0.39
+8.03%beat
Revenue / Est. (USD)
110.00M / 123.20M
-10.71%miss
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
148.70M
156.10M
234.30M
110.00M
Cost of goods sold
94.00M
82.40M
106.10M
84.60M
Cost of revenue
94.00M
82.40M
106.10M
84.60M
Research and development expenses
-600.00K
-
-
300.00K
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
61.60M
46.60M
44.60M
40.40M
Operating expense
77.30M
63.10M
61.80M
51.30M
Total operating expenses
171.30M
145.50M
167.90M
135.90M
Operating income
-22.60M
10.60M
66.40M
-25.90M
Other non operating income
49.80M
13.90M
-
15.30M
EBT including unusual items
-50.70M
13.40M
-166.30M
-36.40M
EBT excluding unusual items
12.50M
13.50M
56.40M
-20.30M
Income tax expense
3.90M
6.60M
13.90M
-3.70M
Effective tax rate
-7.69%
49.25%
-8.36%
10.16%
Other operating expenses
-
-
-
-
Net income
-54.60M
6.80M
-180.20M
-32.70M
Net profit margin
-36.72%
4.36%
-76.91%
-29.73%
Earnings per share
-0.43
0.21
0.60
-0.36
Interest and investment income
-
-
-
-
Interest expense
-14.70M
-11.00M
-10.00M
-9.70M
Net interest expenses
-14.70M
-11.00M
-10.00M
-9.70M
Depreciation and amortization charges
-
-
-
-
EBITDA
2.40M
33.50M
89.90M
-9.30M
Gain or loss from assets sale
-11.20M
800.00K
11.90M
1.60M
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps